[BEGIN TABLE]
 ☑ Filed by the Registrant   o Filed by a Party other than the Registrant  
[END TABLE]
[BEGIN TABLE]
 Check the appropriate box:  
 o   Preliminary Proxy Statement o   Confidential, For Use of the Commission Only (as permitted by Rule 14a-6(e)(2))  
 ☑   Definitive Proxy Statement o   Definitive Additional Materials o   Soliciting Material Pursuant to section 240.14a-12  
[END TABLE]
[BEGIN TABLE]
 Payment of Filing Fee (check the appropriate box):  
 ☑   No fee required.  
 o   Fee computed on table below per Exchange Act Rules 14a-6(i)(1) and 0-11.  
 (1)    Title of each class of securities to which transaction applies:  
 (2)   Aggregate number of securities to which transaction applies:  
 (3)   Per unit price or other underlying value of transaction computed pursuant to Exchange Act Rule 0-11 (set forth the amount on which the filing fee is calculated and state how it was determined):  
 (4)   Proposed maximum aggregate value of transaction:  
 (5)   Total fee paid:  
 o   Fee paid previously with preliminary materials.  
 o   Check box if any part of the fee is offset as provided by Exchange Act Rule 0-11(a)(2) and identify the filing for which the offsetting fee was paid previously. Identify the previous filing by registration statement number, or the Form or Schedule and the date of its filing.  
 (1)   Amount Previously Paid:  
 (2)   Form, Schedule or Registration Statement No.:  
 (3)   Filing Party:  
 (4)   Date filed:  
[END TABLE]
[BEGIN TABLE]
 MEETING AGENDA  
[END TABLE]
[BEGIN TABLE]
 How to Vote Your Shares  
    You may submit proxies by completing, signing and dating the proxy card and mailing it in the accompanying pre-addressed envelope.      You may submit proxies by telephone until 11:59 p.m. (Eastern Time) on January 29, 2019 for shares held directly and until 11:59 p.m. (Eastern Time) on January 27, 2019 for shares held in a Plan by calling 1-800-690-6903. The proxy card includes instructions on submitting proxies by telephone.      You may submit proxies using the Internet until 11:59 p.m. (Eastern Time) on January 29, 2019 for shares held directly and until 11:59 p.m. (Eastern Time) on January 27, 2019 for shares held in a Plan by visiting www.proxyvote.com. The proxy card includes instructions on submitting proxies using the Internet.  
 If you hold shares in a brokerage account, you should follow the instructions provided by your broker to vote your shares by mail, telephone or electronically via the Internet.  
[END TABLE]
[BEGIN TABLE]
 Important Notice Regarding Availability of Proxy Materials for the Annual Meeting to be held on January 30, 2019. On December 14, 2018, we began mailing to our stockholders a Notice of Internet Availability of Proxy Materials (the "Notice") containing instructions on how to access our proxy statement for our 2019 Annual Meeting of Stockholders and our annual report. The Notice, the attached proxy statement and our Annual Report on Form 10-K for the fiscal year ended September 30, 2018, are available at our website at www.brooks.com. It is also available to stockholders without charge upon written request addressed to Investor Relations, Brooks Automation, Inc., 15 Elizabeth Drive, Chelmsford, Massachusetts 01824, which is the mailing address of the Company's principal executive offices. In addition, you may access these materials at www.proxyvote.com, which does not have "cookies" that identify visitors to the site.  
[END TABLE]
[BEGIN TABLE]
GENERAL INFORMATION   1   
Record Date, Voting Rights and Outstanding Shares   1   
Electronic Distribution   1   
Solicitation   1   
Quorum and Required Vote   1   
Voting of Proxies   2   
Revocation of Proxies   3   
Proxy Materials Available via the Internet   3   
CORPORATE GOVERNANCE   4   
Board of Directors   4   
Chairman of the Board   4   
Committees of the Board   5   
Board Risk Oversight   7   
Board Leadership Structure   7   
SECURITY OWNERSHIP OF CERTAIN BENEFICIAL OWNERS AND MANAGEMENT   9   
PROPOSAL NO. 1 ELECTION OF DIRECTORS   11   
Director Qualifications   11   
DIRECTOR NOMINEES   12   
COMPENSATION OF DIRECTORS   18   
Director Compensation Table   18   
Compensation Policy   18   
EXECUTIVE OFFICERS   21   
Biographical Information   20   
COMPENSATION DISCUSSION AND ANALYSIS   22   
Executive Summary   22   
Executive Compensation Program Framework   24   
Fiscal Year 2018 Executive Compensation Program   29   
Other Compensation and Policies   36   
Human Resources and Compensation Committee Report   38   
COMPENSATION TABLES FOR NAMED EXECUTIVE OFFICERS   39   
Summary Compensation Table   39   
Grants of Plan Based Awards Table   40   
Outstanding Equity Awards at Fiscal Year End Table   41   
Stock Vested Table   42   
Nonqualified Deferred Compensation   42   
Pension Benefits   42   
Post-Employment Benefits   43   
[END TABLE]
[BEGIN TABLE]
CEO PAY RATIO   44   
EQUITY COMPENSATION PLAN INFORMATION   45   
RELATED PARTY TRANSACTIONS   45   
PROPOSAL NO. 2 ADVISORY VOTE ON EXECUTIVE COMPENSATION   46    
AUDIT COMMITTEE REPORT   47   
INDEPENDENT AUDITOR FEES AND OTHER MATTERS   48   
PROPOSAL NO. 3 RATIFICATION OF THE SELECTION OF INDEPENDENT REGISTERED PUBLIC ACCOUNTING FIRM   49   
OTHER MATTERS   49   
Section 16(a) Beneficial Ownership Reporting Compliance   49   
Standards of Conduct   49   
Stockholder Proposals and Recommendations For Director   49   
Voting Results   50   
Householding of Proxy Materials   50   
Material Not Incorporated by Reference   50   
Annual Report on Form 10-K   50   
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – Proxy Statement   1  
[END TABLE]
[BEGIN TABLE]
 2   BROOKS AUTOMATION – Proxy Statement  
[END TABLE]
[BEGIN TABLE]
    Stockholders of record may submit proxies by completing, signing and dating their proxy cards and mailing them in the accompanying pre-addressed envelope. Stockholders who are the beneficial owners of shares held in a brokerage account, or by another person on their behalf, may vote by mail by completing, signing and dating the voting instruction card provided by their broker, trustee or nominee and mailing it in the accompanying pre-addressed envelope.  
    Stockholders of record may submit proxies by telephone until 11:59 p.m. (Eastern Time) on January 29, 2019 for shares held directly and until 11:59 p.m. (Eastern Time) on January 27, 2019 for shares held in a Plan. The proxy card includes instructions on submitting proxies by telephone. Most stockholders who are the beneficial owners of shares held in a brokerage account, or by another person on their behalf, may vote by telephone by calling the number specified on the voting instruction card provided by their broker, trustee or nominee. Please see the voting instruction card for telephone voting availability.  
    Stockholders of record may submit proxies using the Internet until 11:59 p.m. (Eastern Time) on January 29, 2019 for shares held directly and until 11:59 p.m. (Eastern Time) on January 27, 2019 for shares held in a Plan by visiting www.proxyvote.com. The proxy card includes instructions on submitting proxies using the Internet. Most stockholders who are the beneficial owners of shares held in a brokerage account, or by another person on their behalf, may vote using the Internet by following the instructions on the voting instruction card provided by their broker, trustee or nominee. Please see the voting instruction card for Internet voting availability.  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – Proxy Statement   3  
[END TABLE]
[BEGIN TABLE]
 4   BROOKS AUTOMATION – 2019 Proxy Statement  
[END TABLE]
[BEGIN TABLE]
 Name of Director   Audit   Executive   Finance   HR & Compensation   Nominating & Governance  
 Non-Employee Directors:                      
 A. Clinton Allen                    
 Robyn C. Davis                    
 Joseph R. Martin(1)                    
 John K. McGillicuddy                   
 Krishna G. Palepu                   
 Kirk P. Pond                    
 Michael Rosenblatt                     
 Alfred Woollacott, III                   
 Mark S. Wrighton                    
 Ellen Zane                   
 Employee Director:                      
 Stephen S. Schwartz                     
 NUMBER OF MEETINGS IN FISCAL 2018   7   9   4   4   4  
[END TABLE]
[BEGIN TABLE]
    Chairman      Member  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – 2019 Proxy Statement   5  
[END TABLE]
[BEGIN TABLE]
 6   BROOKS AUTOMATION – 2019 Proxy Statement  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – 2019 Proxy Statement   7  
[END TABLE]
[BEGIN TABLE]
 8   BROOKS AUTOMATION – 2019 Proxy Statement  
[END TABLE]
[BEGIN TABLE]
Name Shares of Common  Stock Beneficially  Owned(1)  Percentage of  Class(2)  
Named Executive Officers and Current Directors:             
Stephen S. Schwartz   470,961       * 
Lindon G. Robertson   118,281       * 
Maurice H. Tenney III   129,211       * 
David E. Jarzynka   73,063       * 
David C. Gray   53,274       * 
A. Clinton Allen(3)   101,889       * 
Robyn C. Davis(4)   29,868       * 
Joseph R. Martin   85,468       * 
John K. McGillicuddy(5)   88,220       * 
Krishna G. Palepu   91,243       * 
Kirk P. Pond(6)   92,714       * 
Michael Rosenblatt   1,018       * 
Alfred Woollacott, III   85,058       * 
Mark S. Wrighton   102,722       * 
Ellen M. Zane   45,750       * 
All directors and current executive officers as a group (17 persons)(3)(4)(5)(6)(7)   1,769,150     2.45% 
Five Percent Owners:             
BlackRock, Inc., 40 East 52nd Street, New York, NY 10022(8)   8,943,161     12.4% 
The Vanguard Group, Inc., 100 Vanguard Boulevard, Malvern, PA 19355(9)   7,056,228     9.80% 
Dimensional Fund Advisors LP, Palisades West, Building One 6300 Bee Cave Road, Austin, Texas 78746(10)   4,920,279     6.83% 
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – 2019 Proxy Statement   9  
[END TABLE]
[BEGIN TABLE]
 10   BROOKS AUTOMATION – 2019 Proxy Statement  
[END TABLE]
[BEGIN TABLE]
 Our Board of Directors Recommends a Vote FOR Each Nominee for Director  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – Proxy Statement   11  
[END TABLE]
[BEGIN TABLE]
        Director Since October 2003     Age 74   A. Clinton Allen  
     Nominee Information Mr. Allen is chairman and chief executive officer of A.C. Allen & Company, an investment banking consulting firm, and principal of the American College of Corporate Directors, an organization that provides educational and other services to public company directors, chief executive officers and corporate counsel. From 1989 to 2002, Mr. Allen served as vice chairman of the board of Psychemedics Corporation, a biotechnology company with a proprietary drug testing product, and as chairman of the board of Psychemedics from 2002 to 2003. Mr. Allen rejoined the board of Psychemedics in 2015. Mr. Allen is currently the non-executive chairman and a director of Collectors Universe, Inc., a third-party authentication and grading service for high-value collectibles. He also serves as lead director of LKQ Corporation, a supplier of recycled OEM automotive parts. Mr. Allen holds an Executive Master Professional Director Certification from the American College of Corporate Directors.     Qualifications The Board of Directors has concluded that Mr. Allen should continue to serve as a director of the Company because of his broad-based investment banking and financial market expertise, which enables him to provide the Company and the Board with valuable insights in both merger and acquisition analysis and in the approach to capital markets generally, as well as his leadership experience serving as chairman and director for diverse publicly traded companies.  
[END TABLE]
[BEGIN TABLE]
        Director Since June 2013     Age 57       Robyn C. Davis  
     Nominee Information Ms. Davis has been managing director of AngelHealthcare Investors, LLC, an early-stage private equity investment group focused on medical devices, life sciences and specialty pharmaceutical companies, since 2000. Prior to AngelHealthcare, Ms. Davis was a director of the merchant banking services practices for Barents Group, LLC, and a strategy consultant at Bain & Company. Ms. Davis currently serves as a director of SC Repco, Inc., a privately-held company that represents the interests of the former shareholders of Smart Cells, Inc., which was acquired by Merck & Co. in 2010. Ms. Davis also serves as a director of two early-stage, privately-held healthcare companies, Akston Bioscience Corporation and CRA Health, LLC. Ms. Davis holds an Executive Masters Professional Director Certification from the American College of Corporate Directors.     Qualifications The Board of Directors has concluded that Ms. Davis should continue to serve as a director of the Company because of her extensive business experience, particularly with early stage life sciences companies, and her banking and finance expertise.  
[END TABLE]
[BEGIN TABLE]
 12   BROOKS AUTOMATION – Proxy Statement  
[END TABLE]
[BEGIN TABLE]
        Director Since June 2001     Age 71    Joseph R. Martin  
     Nominee Information Mr. Martin has been chairman of the Board since May 2006. Mr. Martin served as executive vice president and chief financial officer, and later senior executive vice president, and then as member of Office of the Chairman of Fairchild Semiconductor International, Inc., a supplier of power semiconductors, from June 1996 to May 2004. He served as the vice chairman of Fairchild's board of directors from 2003 until his retirement in June 2005. Mr. Martin is a member of the board of directors of Collectors Universe, Inc., a publicly traded company that provides third-party authentication and grading service for high-value collectibles, and of Bionik Laboratories Corp. a publicly traded medical device and robotics company focused on developing transformational technologies and solutions for individuals with neurological disorders. He is also a member of the board of directors of Sanken North America, Inc., a privately-held company that owns both Polar Semiconductor, LLC, a wafer fabrication facility, and Allegro MicroSystems, LLC, which manufactures high-performance power and sensing semiconductors. Mr. Martin also serves as a trustee of Embry-Riddle Aeronautical University. Mr. Martin previously served as a director of SynQor, Incorporated, a manufacturer of power converters, until March 2014 and Soitec, Inc., a semiconductor wafer processing company, until July 2017. Mr. Martin holds an Executive Master Professional Director Certification from the American College of Corporate Directors.     Qualifications The Board of Directors has concluded that Mr. Martin should continue to serve as a director of the Company because of his extensive industry and finance experience over more than 30 years in the semiconductor industry as chief financial officer and vice chairman of the board of directors of a multinational public semiconductor company, combined with the leadership that he has provided as Brooks' chairman since 2006. The Board of Directors regards Mr. Martin's experience as invaluable to the operation of the Board and the financial success of the Company.  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – Proxy Statement   13  
[END TABLE]
[BEGIN TABLE]
        Director Since November 2005     Age 64   Krishna G. Palepu  
     Nominee Information Professor Palepu is the Ross Graham Walker Professor of Business Administration and senior advisor to the president of Harvard University. Among his other responsibilities at Harvard Business School, Professor Palepu teaches in several different corporate governance educational programs. Prior to assuming his current administrative position, Professor Palepu held other positions at Harvard Business School since January 1983, including Senior Associate Dean for International Development and Senior Associate Dean for Research. Professor Palepu was formerly a member of the board of directors of Dr. Reddy's Laboratories Ltd., an Indian global pharmaceuticals company, from 2002 until 2009, and PolyMedica Corp, a Massachusetts provider of diabetes testing supplies and products, from June 2006 until it was sold in August 2007. Professor Palepu also serves as a trustee of The Winsor School. Professor Palepu was also formerly a member of the board of directors of BTM Corporation, a privately-owned management solutions provider focused on converging business with technology, and Satyam Computer Services Limited ("Satyam"), an Indian company whose shares were publicly traded in India and on the New York Stock Exchange. In December 2008, Professor Palepu resigned from the board of Satyam. Following his resignation, Satyam has been the subject of significant litigation, a portion of which has included Professor Palepu as a named defendant. For a full discussion of the Satyam litigation as it relates to Professor Palepu, please see the section titled "Pending Legal Matters" below. Professor Palepu holds a Master Professional Director Certification from the American College of Corporate Directors.     Qualifications The Board of Directors has evaluated the matters pertaining to the Satyam litigation as it relates to Professor Palepu, including a re-evaluation after the December 2014 court decision, and concluded that Professor Palepu should continue to serve as a director of the Company because of the depth of the strategic, marketing, financial and technology insights that he provides arising out of his service as a professor at an internationally esteemed business school and his expertise in corporate governance, as well as the global and culturally diverse perspective afforded by his international background.  
[END TABLE]
[BEGIN TABLE]
        Director Since November 2007     Age 74   Kirk P. Pond  
     Nominee Information Mr. Pond was the president and chief executive officer of Fairchild Semiconductor International, Inc., from June 1996 until May 2005. He served as the chairman of Fairchild's board of directors from 1997 until June 2006. Prior to Fairchild Semiconductor's separation from National Semiconductor, Mr. Pond held several executive positions with National Semiconductor, including executive vice president, chief operating officer and in the office of the president. Prior to that, Mr. Pond was executive vice president of Timex, Inc. and vice president of Texas Instruments, Inc. Mr. Pond served as a member of the board of directors of the Federal Reserve Bank of Boston from January 2004 until January 2007 and since 2005 has been a director of WEX Inc., a leading provider of corporate payment solutions. Mr. Pond also has been a director of Sensata Technologies Holding (NV), a sensor and electrical protection device manufacturer, since March 2011 and has served on the advisory board of the University of Arkansas Engineering School since 1987.     Qualifications The Board of Directors has concluded that Mr. Pond should continue to serve as a director of the Company in order to receive the continuing advantage both of his leadership experience as chief executive officer of a successful public company in the semiconductor industry and his generally broad background in technology, semiconductor manufacturing, global marketing and finance in both the public and private sectors.  
[END TABLE]
[BEGIN TABLE]
 14   BROOKS AUTOMATION – Proxy Statement  
[END TABLE]
[BEGIN TABLE]
        Director Since September 2018     Age 71    Michael Rosenblatt  
     Nominee Information Dr. Rosenblatt currently serves as Chief Medical Officer of Flagship Pioneering, a Cambridge, Massachusetts-based firm that originates new biotech companies. Prior to Flagship Pioneering, from 2009 through 2016, he was Executive Vice President and Chief Medical Officer of Merck & Co., Inc., and prior to that he held various academic positions, including as Dean of Tufts University School of Medicine and the Robert Ebert Professor of Molecular Medicine and George R. Minot Professor at Harvard Medical School. Since 2015 Dr. Rosenblatt has been on the board of Rubius Therapeutics, a publicly traded company using advanced cellular approaches that harness properties of red blood cells to generate novel therapies. He has been a director of the following privately owned companies since 2016: Flagship Pioneering's Cobalt Biomedicine, Cygnal Therapeutics, and Ohana Biosciences, and Ferring's USA subsidiary. Dr. Rosenblatt is a member of the Harvard Medical School Board of Fellows, and the research advisory committees of Massachusetts General, Brigham and Women's, and Boston Children's hospitals.     Qualifications The Board has concluded that Dr. Rosenblatt should continue to serve as a director of the Corporation because of his leadership and executive experience in the biotechnology industry, including as the chief medical officer of a major pharmaceutical company and a substantial life sciences venture capital firm, his board-level experience as a founding scientist, scientific advisory board member, or director of more than a dozen biopharmaceutical companies, his academic leadership experience as a dean and professor at prestigious medical schools, and his extensive expertise in drug discovery and medical research.  
[END TABLE]
[BEGIN TABLE]
        Director Since August 2010     Age 59   Stephen S. Schwartz  
     Nominee Information Dr. Schwartz joined Brooks in April 2010 as president and continued to serve as such until August 2013. He was re-appointed president in May 2016. On October 1, 2010, he became chief executive officer and continues to serve in that role. Dr. Schwartz had previously served, from August 2002 until April 20, 2009, as chief executive officer and a director of Asyst Technologies, Inc., a manufacturer of integrated hardware and software automation systems primarily directed at the semiconductor manufacturing industry. He joined Asyst in January 2001 as senior vice president, Product Groups and Operations and was elected chairman of Asyst in January 2003. Asyst filed for bankruptcy protection under Chapter 11 of the United States bankruptcy act on April 24, 2009, and Asyst's assets have since been liquidated. Prior to joining Asyst, Dr. Schwartz had served since 1987 in various capacities with Applied Materials, Inc., including acting as general manager for Applied Material's service business and president of Consilium, Inc., an Applied Materials software subsidiary. Since November 2018, Dr. Schwartz has served on the board of directors of Spire Inc., a publicly traded natural gas company.       Qualifications The Board of Directors has concluded that Dr. Schwartz should continue to serve as a director of the Company because of the depth of industry, marketing and management experience that he brings as former chief executive officer of a company in the automation manufacturing space, as well as the fact that he is the Company's president and chief executive officer, thereby bringing to the Board his insight and experience with the daily business of the Company and its customers, employees and other stakeholders.  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – Proxy Statement   15  
[END TABLE]
[BEGIN TABLE]
        Director Since October 2005     Age 72       Alfred Woollacott, III  
     Nominee Information Mr. Woollacott became a director following the Company's acquisition of Helix Technology Corporation in October 2005. Mr. Woollacott is a certified public accountant and was a partner with the accounting firm of KPMG LLP from 1979 until his retirement in September 2002. He is currently a board member of the William H. Hart Realty Company, Inc. and the Hart Haven Community Association. Mr. Woollacott also served, until 2010, as a director of Greencore U.S. Holdings, a wholly-owned subsidiary of Greencore Group PLC, an Irish corporation listed on the Irish Stock Exchange, which is an international manufacturer of convenience foods and ingredients. Mr. Woollacott holds an Executive Master Professional Director Certification from the American College of Corporate Directors.     Qualifications The Board of Directors has concluded that Mr. Woollacott should continue to serve as a director of the Company because of his financial background and expertise gained through his career as partner of a large, international public accounting firm, as well as his experience on the board of an international company.  
[END TABLE]
[BEGIN TABLE]
        Director Since October 2005     Age 69   Mark S. Wrighton  
     Nominee Information Dr. Wrighton became a director following the Company's acquisition of Helix Technology Corporation in October 2005. Dr. Wrighton has been chancellor of Washington University in St. Louis since July 1995. Dr. Wrighton also serves as a director of Cabot Corporation, a chemical manufacturer, and of Corning Incorporated, a manufacturer of specialty glass and ceramics. He previously served as a director of A.G. Edwards, Inc., a financial services company, until 2007, and he previously served as a director of Akermin, Inc, a private company that ceased operations in 2017. Since 1995 Dr. Wrighton has served as Chancellor and Professor of Chemistry at Washington University in St. Louis, following a 23-year tenure at MIT, first as a faculty member in chemistry and for the last five years as Provost and Professor of Chemistry.      Qualifications The Board of Directors has concluded that Dr. Wrighton should continue to serve as a director of the Company because of his leadership and financial experience gained as the lead executive of an esteemed, large university, as well as his extensive experience as a member of the board for large, technology focused public companies in the manufacturing and financial sectors and his technology experience as a scientist.  
[END TABLE]
[BEGIN TABLE]
 16   BROOKS AUTOMATION – Proxy Statement  
[END TABLE]
[BEGIN TABLE]
        Director Since May 2012     Age 67   Ellen M. Zane  
     Nominee Information Ms. Zane is serving as CEO Emeritus and vice chair of the board of trustees at Tufts Medical Center & Floating Hospital for Children, and from 2004 to 2011, she served as its president and chief executive officer. From May 1994 to January 2004, Ms. Zane served as Network President for Partners Healthcare System, a physician/hospital network sponsored by the Harvard affiliated Massachusetts General Hospital and Brigham and Women's Hospital. Prior to 2004, Ms. Zane served as chief executive officer of Quincy Hospital in Quincy, Massachusetts. Ms. Zane is also currently a member of the board of directors at Boston Scientific Corporation, a publicly traded worldwide medical devices provider, Haemonetics Corporation, a publicly traded worldwide medical devices provider since January 2018 and previously from 2012 to 2016, Fiduciary Trust Company, a privately owned wealth management company, AgNovos Healthcare, LLC a privately-held medical device company, focused on bone health, and nThrive, a privately owned healthcare revenue cycle management company . Ms. Zane previously served as a director of Lincare Holdings Inc. until August 2012, Press Ganey until October 2016, Century Capital Management until June of 2017 and Parexel International Corporation until September 2017. Ms. Zane holds a Professional Director Certification from the American College of Corporate Directors.     Qualifications The Board of Directors has concluded that Ms. Zane should continue to serve as a director of the Company because of her executive experience in the health care industry, including as the chief executive officer of a large medical center, in addition to her substantial experience as a director at other public companies.  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – Proxy Statement   17  
[END TABLE]
[BEGIN TABLE]
Name Fees Earned or  Paid in cash Stock Awards(1) Total 
Joseph R. Martin $ 140,000   $ 130,012   $ 270,012   
Ellen M. Zane $ 120,000   $ 90,016   $ 210,016   
John K. McGillicuddy $ 112,500   $ 90,016 (2)  $ 202,516   
Krishna G. Palepu $ 105,000   $ 90,016   $ 195,016   
Alfred Woollacott, III $ 102,500   $ 90,016   $ 192,516   
A. Clinton Allen $ 100,000   $ 90,016   $ 190,016   
Robyn C. Davis $ 95,000   $ 90,016   $ 185,016   
Kirk P. Pond $ 95,000   $ 90,016 (3)  $ 185,016   
Mark S. Wrighton $ 95,000   $ 90,016   $ 185,016   
Michael Rosenblatt $ 0   $ 36,740 (4)  $ 36,740   
[END TABLE]
[BEGIN TABLE]
 18   BROOKS AUTOMATION – 2019 Proxy Statement  
[END TABLE]
[BEGIN TABLE]
Name Number of Deferred  Restricted Stock Units 
A. Clinton Allen   7,926   
Robyn C. Davis   22,734   
John K. McGillicuddy   78,720   
Kirk P. Pond   43,569   
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – 2019 Proxy Statement   19  
[END TABLE]
[BEGIN TABLE]
 Name   Age   Position with the Company  
 Stephen S. Schwartz   59   Chief Executive Officer and President  
 Lindon G. Robertson   57   Executive Vice President and Chief Financial Officer  
 Maurice H. Tenney III   55   President, Brooks Life Sciences  
 David E. Jarzynka   50   President, Brooks Semiconductor Solutions Group  
 Guojuan Liao   53   President, GENEWIZ  
 David C. Gray   53   Senior Vice President, Chief Strategy and New Business Officer  
 William T. Montone   66   Senior Vice President, Human Resources  
 Jason W. Joseph   48   Senior Vice President, General Counsel and Secretary  
 David F. Pietrantoni   45   Vice President, Finance and Corporate Controller and Principal Accounting Officer  
[END TABLE]
[BEGIN TABLE]
 20   BROOKS AUTOMATION – 2019 Proxy Statement  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – 2019 Proxy Statement   21  
[END TABLE]
[BEGIN TABLE]
 Name   Role  
 Stephen S. Schwartz   Chief Executive Officer and President  
 Lindon G. Robertson   Executive Vice President and Chief Financial Officer  
 Maurice H. Tenney III   President, Brooks Life Science Systems  
 David E. Jarzynka   President, Brooks Semiconductor Solutions Group  
 David C. Gray   Senior Vice President, Chief Strategy and New Business Officer  
[END TABLE]
[BEGIN TABLE]
 22   BROOKS AUTOMATION – 2019 Proxy Statement  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – 2019 Proxy Statement   23  
[END TABLE]
[BEGIN TABLE]
 Strategic Imperatives  
 Drive performance  
• Extend our leadership position in our core markets  
• Expand our comprehensive sample management business in the life sciences market with organic and acquisition investments  
• Exercise balanced and disciplined capital deployment  
 Deliver profitable growth  
• Drive margin expansion in each of our two core businesses  
• Achieve rapid growth of life sciences revenue  
[END TABLE]
[BEGIN TABLE]
 24   BROOKS AUTOMATION – 2019 Proxy Statement  
[END TABLE]
[BEGIN TABLE]
 What We Do   What We Don't Do  
    Maintain robust stock ownership guidelines      No above-median pay benchmarking  
    Maintain robust clawback provisions       No gross-up provisions  
    Provide for double-trigger change-in-control benefits      No pension plans or other post-employment benefit plans  
    Consult with an independent compensation consultant      No executive perquisites  
    Conduct an annual risk assessment      No severance multipliers in excess of 3 times total pay  
    Conduct an annual review of pay levels      No dividends on RSUs until they vest  
    Conduct evaluations of performance goal rigor      No hedging or pledging of Company stock  
    Solicit shareholder input and incorporate their feedback          
    Require minimum vesting periods on equity awards          
[END TABLE]
[BEGIN TABLE]
 Element   Objectives  
 Base Salary• Provides regular source of income at market-competitive levels  
 PBVC Plan• Motivates executive team to achieve key annual financial goals and objectives  
• Provides at-risk compensation that is not earned if minimum threshold goals are not achieved as well as upside earnings potential for achievement of stretch goals   
 LTIP• Motivates executive team to execute against longer-term financial and strategic objectives  
• Performance-based RSUs provide a direct link between performance outcomes and actual pay realized; payout is contingent upon achieving minimum performance thresholds, and provides upside potential for stretch performance  
• Time-based RSUs provide retention incentive  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – 2019 Proxy Statement   25  
[END TABLE]
[BEGIN TABLE]
• Executive compensation program development   
• PBVC and LTIP design, performance metrics, and goals  
• Executive base salary adjustments  
[END TABLE]
[BEGIN TABLE]
 26   BROOKS AUTOMATION – 2019 Proxy Statement  
[END TABLE]
[BEGIN TABLE]
• Incentive plan achievement awards and payouts  
• Pay programs and policies that impact the executive team such as severance and change in control arrangements, stock ownership requirements and other pay governance items  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – 2019 Proxy Statement   27  
[END TABLE]
[BEGIN TABLE]
 Step   Selection Criteria  
 1.   Industry Similarity   »   Publicly-traded companies in the Semiconductors & Semiconductor Equipment (GICS: 4530), Health Care Equipment & Services (GiCS: 3510) or Pharmaceuticals, Biotechnology & Life Sciences (GICS: 3520) industry groups  
 2.   Geographic Similarity   »   US-based companies  
 3.   Size Similarity   »   Revenue: $210M - $1.9B, approximating 0.33x - 3.0x range around Brooks' trailing four-quarter revenue  
 »   Market Capitalization: $500M - $4.5B, approximating a 0.33x - 3.0x range around Brooks' current market capitalization  
 4.   Business Profile Similarity   »   Preference given to companies in the semiconductor industry and/or companies with a presence in the life sciences equipment market a)   Those with comparable products/services b)   Those that serve the life sciences market to some degree to reflect Brooks' business strategy of expanding its life sciences segment with its sample management systems and services  
[END TABLE]
[BEGIN TABLE]
 28   BROOKS AUTOMATION – 2019 Proxy Statement  
[END TABLE]
[BEGIN TABLE]
 Fiscal 2017 Peer Group:   Fiscal 2018 Peer Group:  
 Advanced Energy Industries, Inc.   Advanced Energy Industries, Inc.  
 Analogic Corp.   Analogic Corp.  
 Axcelis Technologies, Inc.   Axcelis Technologies, Inc.  
 Bruker Corporation   Bio-Rad Laboratories, Inc.  
 Cabot Microelectronics Corporation   Bruker Corporation  
 Coherent, Inc.   Cabot Microelectronics Corporation  
 Entegris, Inc.   Coherent, Inc.  
 FormFactor, Inc.   Entegris, Inc.  
 MKS Instruments, Inc.   FormFactor, Inc.  
 MTS Systems Corporation   Haemonetics Corporation  
 Photronics, Inc.   MKS Instruments, Inc.  
 Ultra Clean Holdings, Inc.   MTS Systems Corporation  
 Veeco Instruments, Inc.   Photronics, Inc.  
 Xcerra Corp.   Ultra Clean Holdings, Inc.  
     Varex Imaging Corporation  
     Veeco Instruments, Inc.  
[END TABLE]
[BEGIN TABLE]
 Fiscal Year 2018 Element   Fiscal Year 2018 Outcome  
 Base Salary• Dr. Schwartz and Messrs. Robertson, Tenney, Jarzynka and Gray received base salary adjustments effective January 1, 2018.   
 Annual PBVC Cash Incentive Plan• Corporate Revenue reached the midpoint between the target goal and the stretch goal.   
• Adjusted Gross Margin exceeded the target goal and the stretch goal.  
• Adjusted Earnings Per Share reached the midpoint between the target goal and the stretch goal.   
 Long-term Incentive Plan (2016 - 2018) Status: Complete. Final Achievement 171.9%• 3-Year metric Measures: Cumulative Adjusted Operating Profit for Fiscal 2016 – 2018, Life Sciences Revenue at Fiscal Year End 2018 and 3-year Average ROIC for Fiscal 2016 – 2018 together achieved 171.9% of weighted targets and participants vested in corresponding RSUs   
 Long-term Incentive Plan (2017 - 2019) Status: Ongoing• 3-Year metric Measures: cumulative Adjusted Operating Profit; cumulative Free Cash Flow; and three year average ROIC to be measured following the end of Fiscal 2019.   
 Long-term Incentive Plan (2018 - 2020) Status: Ongoing• 3-Year metric Measures: cumulative Adjusted Operating Profit; cumulative Free Cash Flow; and three year average ROIC to be measured following the end of Fiscal 2020.  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – 2019 Proxy Statement   29  
[END TABLE]
[BEGIN TABLE]
 Name   September 30, 2017   September 30, 2018   Percent Increase  
 Stephen S. Schwartz   $625,000   $650,000   4%  
 Lindon G. Robertson   $440,000   $485,000   10%   
 Maurice H. Tenney III   $435,000   $465,000   7%   
 David E. Jarzynka    $350,000    $380,000    9%  
 David C. Gray   $350,000   $360,000   3%  
[END TABLE]
[BEGIN TABLE]
 30   BROOKS AUTOMATION – 2019 Proxy Statement  
[END TABLE]
[BEGIN TABLE]
 Perspectives   Finding   Sufficient Rigor  
 1.   Historical Outcome Analysis   Payouts have fluctuated, highlighting history of sufficiently challenging goals   √  
 2.   Internal Y/Y Growth Analysis   Goals at target represent significant and meaningful year-over-year growth   √  
 3.   Investor Expectations Analysis   FY18 targets are aligned with investor expectations   √  
 4.   Peer Goal Analysis   Performance ranges and award slopes are generally consistent with peers, although the upside slope on EPS is flatter to increase difficulty of achieving maximum payout   √  
[END TABLE]
[BEGIN TABLE]
    TARGETS ACHIEVEMENT 
Corporate Metric  Weighting 25% 100% Max Full Year  Result Target Award Percent 
CEO NEOs 
Annual Revenue ($000)   25% $ 695M   $ 760M   $ 810M   $ 816M     200%   150% 
Adjusted Gross Margin   25%   39.4%   41.0%   42.0%   41.4%   137%   118.3% 
Adjusted Earnings Per Share   50% $ 1.20   $ 1.35   $ 1.75   $ 1.55     150.4%   125.2% 
    100%                                     
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – 2019 Proxy Statement   31  
[END TABLE]
[BEGIN TABLE]
Name Target Opportunity as% of Fiscal Base Pay Cash Payout Payment as a% of Target 
Stephen S. Schwartz   110% $ 1,052,563     149% 
Lindon G. Robertson   100% $ 614,335     130% 
Maurice H. Tenney III   80% $ 321,771     88% 
David E. Jarzynka   75% $ 396,349     142% 
David C. Gray   60% $ 278,153     130% 
[END TABLE]
[BEGIN TABLE]
 32   BROOKS AUTOMATION – 2019 Proxy Statement  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – 2019 Proxy Statement   33  
[END TABLE]
[BEGIN TABLE]
 Long Term Incentive Plan Objectives – LTIP 2016 - 2018          
 Strategic Objective   Weighting   Measurement Time Frame   Metrics   Threshold 25% of Award   Target 100% of Award   Maximum  +200% of  Award   Results   Weighted%  of Target Earned  
 Adjusted Operating Profit(1)    40%   3 Years   Cumulative  Adjusted Operating  Profit 2016 - 2018   $100M   $160M   $225M   $257.3M   80%  
 Life Sciences Revenue(2)    40%   3 Years   FY18 Life Sciences  Revenue    $130M   $170M   $220M   $196.5M   61.2%  
 ROIC: (with acquisitions)(3)   20%   3 Years   3 year average ROIC   5%   7.5%   12%   9.9%   30.7%  
 Total                               171.9%  
[END TABLE]
[BEGIN TABLE]
  LTIP 2016 - 2018     
Name Time-Based RSUs Performance-Based PSUs Granted at Target Additional PSUs Earned Above Target Total PSUs Earned (vest 11/6/18) 
Stephen S. Schwartz    38,750     116,250     83,584     199,834   
Maurice H. Tenney III    20,000     60,000     43,140     103,140   
Lindon G. Robertson    17,500     52,500     37,748     90,248   
David E. Jarzynka    11,250     33,750     24,266     58,016   
David C. Gray    11,250     33,750     24,266     58,016   
[END TABLE]
[BEGIN TABLE]
 34   BROOKS AUTOMATION – 2019 Proxy Statement  
[END TABLE]
[BEGIN TABLE]
 Long Term Incentive Plan Objectives – LTIP 2017 - 2019  
 Strategic Objective   Weighting   Measurement  Time Frame   Metrics   Threshold  25% of Award   Target 100%  of Award   Maximum  +200% of  Award  
 Adjusted Operating Profit(1)   40%   3 Years   Cumulative  Adjusted Operating  Profit (2017 - 2019)   *   *   *  
 Free Cash Flow(2)   40%   3 Years   Cumulative Free Cash  Flow (2017-2019)   *   *   *  
 ROIC: (with acquisitions)(3)   20%   3 Years   3 year average ROIC   *   *   *  
[END TABLE]
[BEGIN TABLE]
 Long Term Incentive Plan Objectives – LTIP 2018 - 2020  
 Strategic Objective   Weighting   Measurement  Time Frame   Metrics   Threshold  25% of Award   Target 100%  of Award   Maximum  +200% of  Award  
 ROIC (with acquisitions)(1)   34%   3 Years    3 year average ROIC  (2018 – 2020)   *   *   *  
 Free Cash Flow(2)   33%   3 Years   Cumulative Free Cash  Flow (2018-2020)   *   *   *  
 Adjusted Operating Profit(3)   33%   3 Years   Cumulative Adjusted Operating Profit (2018 - 2020)    *   *   *  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – 2019 Proxy Statement   35  
[END TABLE]
[BEGIN TABLE]
 36   BROOKS AUTOMATION – 2019 Proxy Statement  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – 2019 Proxy Statement   37  
[END TABLE]
[BEGIN TABLE]
 38   BROOKS AUTOMATION – 2019 Proxy Statement  
[END TABLE]
[BEGIN TABLE]
Name and  Principal Position Fiscal  Year Salary Bonus Stock  Awards(1) Non-Equity  Incentive Plan  Compensation(2) All Other  Compensation Total 
Stephen S. Schwartz   2018   $ 643,750 (8)        $ 2,217,307   $ 1,052,563   $ 12,375 (3)  $ 3,925,995   
President and  Chief Executive Officer   2017   $ 625,000         $ 2,061,640   $ 1,195,031   $ 12,150   $ 3,893,821   
  2016   $ 625,000         $ 1,760,800   $ 490,625   $ 12,375   $ 2,888,800   
Lindon G. Robertson   2018   $ 473,750 (9)        $ 1,061,135   $ 614,335   $ 12,375 (4)  $ 2,161,595   
Executive Vice President  & Chief Financial Officer   2017   $ 436,250         $ 908,236   $ 597,575   $ 12,150   $ 1,954,211   
  2016   $ 425,000         $ 795,200   $ 314,500   $ 113,462   $ 1,648,163   
Maurice H. Tenney III   2018   $ 457,500 (10)        $ 909,569   $ 321,771   $ 12,375 (5)  $ 1,701,215   
President, Brooks  Life Sciences   2017   $ 432,500   $ 100,000   $ 891,520   $ 236,485   $ 12,150   $ 1,672,655   
  2016   $ 425,000         $ 908,800   $ 214,917   $ 108,223   $ 1,656,941   
David E. Jarzynka   2018   $ 372,500 (11)        $ 667,008   $ 396,349   $ 13,829 (6)  $ 1,449,686   
President, Brooks Semiconductor Solutions Group   2017   $ 346,250         $ 626,850   $ 359,641   $ 12,719   $ 1,345,460   
  2016   $ 319,192         $ 798,300   $ 188,044   $ 12,802   $ 1,318,338   
David C. Gray   2018   $ 357,500 (12)        $ 545,728   $ 278,153   $ 12,470 (7)  $ 1,193,851   
Senior Vice President, Chief Strategy and New Business Officer   2017   $ 350,000         $ 487,550   $ 287,658   $ 12,115   $ 1,137,323   
  2016   $ 350,000         $ 511,200   $ 157,500   $ 11,960   $ 1,030,660   
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – Proxy Statement   39  
[END TABLE]
[BEGIN TABLE]
    Estimated Future Payouts  Under Non-Equity  Incentive Plan Awards(1) Estimated Future Payouts  Under Equity Incentive  Plan Awards All Other  Stock Awards:  Number of  Shares of  Stock or Units  (#) Grant Date  Fair Value of  Stock Awards  ($) 
Name Grant Date Target  ($) Maximum  ($) Threshold  (#) Target  (#) Maximum  (#) 
Stephen S. Schwartz       $ 715,000   $ 1,430,000                                 
    11/8/2017(2)                                  16,180   $ 554,327   
    11/8/2017(3)                12,135     48,540     97,080         $ 1,662,980   
Lindon G. Robertson       $ 485,000   $ 727,500                                 
    11/8/2017(2)                                  7,743   $ 265,275   
    11/8/2017(3)                5,808     23,230     46,460         $ 795,860   
Maurice H. Tenney III       $ 372,000   $ 558,000                                 
    11/8/2017(2)                                  6,637   $ 227,384   
    11/8/2017(3)                4,978     19,912     39,824         $ 682,185   
David E. Jarzynka       $ 285,000   $ 427,500                                 
    11/8/2017(2)                                  4,867   $ 166,743   
    11/8/2017(3)                3,651     14,602     29,204         $ 500,265   
David C. Gray       $ 216,000   $ 324,000                                 
    11/8/2017(2)                                  3,982   $ 136,423   
    11/8/2017(3)                2,987     11,947     23,894         $ 409,304   
[END TABLE]
[BEGIN TABLE]
 40   BROOKS AUTOMATION – Proxy Statement  
[END TABLE]
[BEGIN TABLE]
  Stock Awards 
Name Number of  Shares or Units of  Stock That Have  Not Vested (#) Market Value of  Shares or Units of  Stock That Have Not  Vested ($)(9) Number of Equity Incentive  Plan Awards; Number  of Unearned Shares, Units  or Other Rights That  Have Not Vested (#) Equity Incentive Plan  Awards: Market or Payout  Value of Unearned Shares,  Units or Other Rights That  Have Not Vested ($) 
Stephen S. Schwartz   12,919 (1)  $ 452,553               
                116,250 (2)  $ 4,072,238   
    24,667 (3)  $ 864,085               
                111,000 (4)  $ 3,888,330   
    16,180 (5)  $ 566,785               
                48,540 (6)  $ 1,700,356   
Lindon G. Robertson   5,834 (1)  $ 204,365               
                52,500 (2)  $ 1,839,075   
    10,867 (3)  $ 380,671               
                48,900 (4)  $ 1,712,967   
    7,743 (5)  $ 271,237               
                23,230 (6)  $ 813,747   
Maurice H. Tenney III   6,668 (1)  $ 233,580               
                60,000 (2)  $ 2,101,800   
    10,667 (3)  $ 373,665               
                48,000 (4)  $ 1,681,440   
    6,637 (5)  $ 232,494               
                19,912 (6)  $ 697,517   
David E. Jarzynka   3,750 (1)  $ 131,263               
                33,750 (2)  $ 1,182,263   
    7,500 (3)  $ 262,725               
                33,750 (4)  $ 1,182,263   
    4,867 (5)  $ 170,491               
                14.602 (6)  $ 511,508   
    6,000 (7)  $ 210,180               
                5,346 (8)  $ 187,270   
David C. Gray   3,750 (1)  $ 131,363               
                33,750 (2)  $ 1,182,263   
    5,833 (3)  $ 204,330               
                26,250 (4)  $ 919,538   
    3,982 (5)  $ 139,489               
                11,947 (6)  $ 418,503   
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – Proxy Statement   41  
[END TABLE]
[BEGIN TABLE]
  Stock Awards 
Name Number of Shares  Acquired on Vesting  (#) Value Realized  on Vesting  ($)(1) 
Stephen S. Schwartz   88,806   $ 2,934,064   
Lindon G. Robertson   41,058   $ 1,358,793   
Maurice H. Tenney III   66,791   $ 2,236,857   
David E. Jarzynka   36,720   $ 1,187,526   
David C. Gray   23,350   $ 774,148   
[END TABLE]
[BEGIN TABLE]
 42   BROOKS AUTOMATION – Proxy Statement  
[END TABLE]
[BEGIN TABLE]
Name Event Salary &  Other Cash  Payment Health  Insurance  Contribution Vesting of  Stock Awards Total 
Stephen S. Schwartz Termination Without Cause or for Good Reason $ 650,000 (1)  $ 10,973   $     $ 660,973   
  Change of Control with Termination $ 2,730,000 (2)  $ 25,695   $ 11,544,347 (3)  $ 14,300,042   
Lindon G. Robertson Termination Without Cause or for Good Reason $ 485,000 (1)  $ 14,874   $     $ 499,874   
  Change of Control with Termination $ 1,940,000 (2)  $ 36,119   $ 5,222,062 (3)  $ 7,198,181   
Maurice H. Tenney III Termination Without Cause or for Good Reason $ 465,000 (1)  $ 10,973   $     $ 475,973   
  Change of Control with Termination $ 1,674,000 (2)  $ 25,247   $ 5,320,496 (3)  $ 7,019,743   
David E. Jarzynka Termination Without Cause or for Good Reason $ 190,000 (4)  $ 7,437   $     $ 197,437   
  Change of Control with Termination $ 1,330,000 (2)  $ 35,362   $ 3,837,963 (3)  $ 5,203,325   
David C. Gray Termination Without Cause or for Good Reason $ 180,000 (4)  $ 7,755   $     $ 187,755   
  Change of Control with Termination $ 1,152,000 (2)  $ 33,564   $ 2,995,486 (3)  $ 4,181,050   
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – Proxy Statement   43  
[END TABLE]
[BEGIN TABLE]
 44   BROOKS AUTOMATION – Proxy Statement  
[END TABLE]
[BEGIN TABLE]
Plan Category Number of  Securities to be  Issued Upon Exercise  of Outstanding  Options, Warrants  and Rights Weighted-Average  Exercise Price  of Outstanding  Options, Warrants and Rights Number of Securities  Remaining Available for  Future Issuance  Under Equity  Compensation  Plans(2) 
Equity compensation plans approved by security holders(1)   2,194,512   $ 17.20     4,130,297 (3)  
Equity compensation plans not approved by security holders   0               
Total   2,194,512           4,130,297   
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – Proxy Statement   45  
[END TABLE]
[BEGIN TABLE]
 THE BOARD OF DIRECTORS BELIEVES THAT THE PROPOSAL TO APPROVE, ON A  NON-BINDING, ADVISORY BASIS, THE EXECUTIVE COMPENSATION CONTAINED IN THE  PROXY STATEMENT IS IN THE BEST INTERESTS OF BROOKS AND OUR STOCKHOLDERS  AND THEREFORE RECOMMENDS A VOTE "FOR" THIS PROPOSAL.  
[END TABLE]
[BEGIN TABLE]
 46   BROOKS AUTOMATION – Proxy Statement  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – Proxy Statement   47  
[END TABLE]
[BEGIN TABLE]
  2018 2017 
Audit Fees $ 3,279,277   $ 2,026,500   
Audit-Related Fees $ 294,129   $ 148,850   
Tax Fees $ 157,077   $ 148,500   
All Other Fees $ 2,756   $ 3,000   
[END TABLE]
[BEGIN TABLE]
 48   BROOKS AUTOMATION – Proxy Statement  
[END TABLE]
[BEGIN TABLE]
 THE BOARD OF DIRECTORS DEEMS PROPOSAL NO. 3 TO BE IN THE BEST INTERESTS OF BROOKS AND  OUR STOCKHOLDERS AND THEREFORE RECOMMENDS THAT THE STOCKHOLDERS VOTE "FOR"  PROPOSAL NO. 3.  
[END TABLE]
[BEGIN TABLE]
 BROOKS AUTOMATION – Proxy Statement   49  
[END TABLE]
[BEGIN TABLE]
 IT IS IMPORTANT THAT PROXIES BE AUTHORIZED PROMPTLY.  THEREFORE, STOCKHOLDERS ARE URGED TO COMPLETE, SIGN AND RETURN  THE ACCOMPANYING FORM OF PROXY IN THE ENCLOSED ENVELOPE.  
[END TABLE]
[BEGIN TABLE]
 50   BROOKS AUTOMATION – Proxy Statement  
[END TABLE]
 